Business

August 5, 2014 11:09 AM

Durham’s BioCryst falls short of analyst expectations in Q2

Durham drug developer BioCryst Pharmaceuticals revenue doubled in the second quarter as the company got a boost from federal funding for its treatment for Marburg virus infection, which is almost indistinguishable from Ebola virus fever.

Related content

Comments

Videos

Today's Market

Nasdaq
Powered by Barchart

Editor's Choice Videos

Raleigh Top Jobs

View All Top Jobs